GG&G

[walker_429]

I agree with you Simps. “The point is he has not capitalized on the potential of his product (WSJ) 09' for a decade.”

Biel should have brought the Actipatch and Allay to the OTC market as a wellness product and could have had 10+ years of sales. This would have allowed a proof of concept to develop that the product works for many ailments, while building the brand. RecoveryRX should have been the medical device going through the grueling and expensive FDA process while sales of Actipatch covered some of the costs instead of the massive dilution.

Of course this is 18 billion shares ago.....

But better late than never and things do seem to be moving forward with the company.

GLTA